

	Quarter Ended
	March 31,			June 30,			September 30,			December 31,
	(in thousands, except per share data)
2016 (1)
Total revenues	$	963,539		$	920,887		$	884,335		$	1,241,513
Gross profit	$	274,834		$	288,669		$	326,863		$	484,935
(Loss) income from continuing operations	$	(88,763	)	$	389,812		$	(191,496	)	$	(3,333,325	)
Discontinued operations, net of tax	$	(45,108	)	$	(46,216	)	$	(27,423	)	$	(4,531	)
Net (loss) income attributable to Endo International plc	$	(133,869	)	$	343,578		$	(218,919	)	$	(3,337,856	)
Net (loss) income per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	(0.40	)	$	1.75		$	(0.86	)	$	(14.96	)
Discontinued operations	(0.20		)	(0.21		)	(0.12		)	(0.02		)
Basic	$	(0.60	)	$	1.54		$	(0.98	)	$	(14.98	)
Net (loss) income per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	(0.40	)	$	1.75		$	(0.86	)	$	(14.96	)
Discontinued operations	(0.20		)	(0.21		)	(0.12		)	(0.02		)
Diluted	$	(0.60	)	$	1.54		$	(0.98	)	$	(14.98	)
Weighted average shares—Basic	222,302			222,667			222,767			222,870
Weighted average shares—Diluted	222,302			222,863			222,767			222,870
2015 (2)
Total revenues	$	714,128		$	735,166		$	745,727		$	1,073,697
Gross profit	$	329,862		$	296,308		$	303,268		$	263,629
Income (loss) from continuing operations	$	150,492		$	(90,894	)	$	(803,706	)	$	443,709
Discontinued operations, net of tax	$	(226,210	)	$	(159,632	)	$	(246,782	)	$	(562,302	)
Net loss attributable to Endo International plc	$	(75,718	)	$	(250,419	)	$	(1,050,442	)	$	(118,463	)
Net loss per share attributable to Endo International plc ordinary shareholders—Basic:
Continuing operations	$	0.89		$	(0.49	)	$	(3.84	)	$	1.98
Discontinued operations	(1.34		)	(0.86		)	(1.18		)	(2.51		)
Basic	$	(0.45	)	$	(1.35	)	$	(5.02	)	$	(0.53	)
Net loss per share attributable to Endo International plc ordinary shareholders—Diluted:
Continuing operations	$	0.85		$	(0.49	)	$	(3.84	)	$	1.97
Discontinued operations	(1.28		)	(0.86		)	(1.18		)	(2.50		)
Diluted	$	(0.43	)	$	(1.35	)	$	(5.02	)	$	(0.53	)
Weighted average shares—Basic	169,653			185,328			209,274			224,147
Weighted average shares—Diluted	176,825			185,328			209,274			225,321

__________

(1)

(Loss) income from continuing operations for the year ended December 31, 2016 was impacted by (1) acquisition-related and integration items of $12.6 million, $48.2 million, $19.5 million and $7.4 million during the first, second, third and fourth quarters, respectively; these costs are net of a benefit due to changes in the fair value of contingent consideration of $10.7 million and $1.0 million during the first and fourth quarters, respectively, and include charges of $23.9 million and $11.6 million during the second and third quarters, respectively (2) asset impairment charges of $129.6 million, $40.0 million, $93.5 million and $3,518.1 million during the first, second, third and fourth quarters, respectively (3) inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans of $68.5 million, $29.1 million, $14.2 million and $13.9 million during the first, second, third and fourth quarters, respectively (4) certain integration costs and separation benefits incurred in connection with continued efforts to enhance the Company’s operations and other miscellaneous costs of $38.5 million, $22.2 million, $9.8 million and $37.1 million during the first, second, third and fourth quarters, respectively, and (5) other charges related to litigation-related and other contingent matters totaling $5.2 million, $5.3 million and $18.3 million during the first, second and third quarters, respectively, and a reduction of charges of $4.8 million during the fourth quarter.

(2)

Income (loss) from continuing operations for the year ended December 31, 2015 was impacted by (1) acquisition-related and integration items of $34.6 million, $44.2 million, $(27.7) million and $54.1 million during the first, second, third and fourth quarters, respectively; these costs are net of a benefit due to changes in the fair value of contingent consideration of $0.8 million, $2.5 million, and $80.3 million during the first, second and third quarters, respectively and a charge of $17.9 million during the fourth quarter (2) asset impairment charges of $7.0 million, $70.2 million, $923.6 million and $139.9 million during the first, second, third and fourth quarters (3) inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans of $39.9 million, $48.9 million, $42.9 million and $117.7 million during the first, second, third and fourth quarters, respectively (4) certain integration costs and separation benefits incurred in connection with continued efforts to enhance the Company’s operations and other miscellaneous costs of $41.8 million, $5.8 million, $22.7 million and $55.2 million during the first, second, third and fourth quarters, respectively (5) other charges related to litigation-related and other contingent matters totaling $13.0 million, $6.9 million and $17.2 million during the first, second and fourth quarters, respectively (6) loss on extinguishment of debt of $1.0 million, $40.9 million and $25.6 million during the first, third and fourth quarters, respectively (7) costs associated with unused financing commitments of $11.8 million, $2.3 million and $64.3 million during the first, second and third quarters, respectively, (8) a charge of $18.9 million for an other-than-temporary impairment of equity investment of during the second quarter and (9) a charge of $37.6 million for the acceleration of Auxilium employee equity awards at closing during the first quarter.